<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> patients are at an increased risk of developing <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e>, including <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It is unknown if these patients are at higher risk of dying from pulmonary resection due to <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or if they have reasonable long-term survival </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We identified 47 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients, seven of which had active <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and forty with a history of <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, who underwent resection for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> between 1998 and 2008 </plain></SENT>
<SENT sid="3" pm="."><plain>We matched <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients with <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> patients who had no <z:hpo ids='HP_0002665'>lymphoma</z:hpo> based on age, gender, surgery type, comorbidities, stage, and histology </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed differences in the length of hospitalization, morbidity, mortality, and overall and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> specific survival between the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> group and the matched no <z:hpo ids='HP_0002665'>lymphoma</z:hpo> group </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We found no significant difference in length of hospitalization, morbidity, or mortality between the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and matched no <z:hpo ids='HP_0002665'>lymphoma</z:hpo> group </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:hpo ids='HP_0002665'>lymphoma</z:hpo> group's 5-year overall survival rate (35%) was significantly lower than that of the no <z:hpo ids='HP_0002665'>lymphoma</z:hpo> group (67%; p = 0.04) </plain></SENT>
<SENT sid="7" pm="."><plain>However, the difference in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>-specific survival between the groups was not significant </plain></SENT>
<SENT sid="8" pm="."><plain>The cause-of-<z:hpo ids='HP_0011420'>death</z:hpo> analysis revealed that <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients also died from recurrent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate analysis revealed that older age, higher stage, and active <z:hpo ids='HP_0002665'>lymphoma</z:hpo> status were significant adverse predictors of survival </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: There is no significant increase in operative morbidity and mortality for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients having pulmonary resection for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The survival for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients is decreased but still acceptable with no difference in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>-specific survival </plain></SENT>
</text></document>